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1. Introduction
  Liver cancer is a malignant cancer in liver, including 
primary and metastasized cancer. China is a country where 
hepatitis B outbreaks frequently, and a large number of 
patients develop liver cancer based on liver cirrhosis. 
Besides, there is usually no obvious symptom in the 
early stage. The patients are already in the intermediate 
or advanced stage when being diagnosed, and liver 
transplantation is the only treatment[1]. The problem is that 
there are too limited liver donors to meet the needs of most 
patients. Since 1990s, researchers have established induced 
pluripotent stem (IPS) cells from fibrocytes to provide a 
novel approach for the treatment of liver cancer[2]. We 
established and identified pluripotent stem cells induced 
from from fibrocytes in liver cancer patients. 
2. Materials and methods
2.1. Materials
  Liver tissues were excised from liver cancer patients 
during April, 2009-April, 2011 in People’s Hospital of 
Zhengzhou, China. The pMXs-IRES-Sox2, pMXs-IRES-
Klf4 and pMXs-IRES-Oct4 virus vectors were obtained 
from Addgene Company. The plasmid extraction kit was 
purchased from Omega Company. LipofectamineTM 2000 
was purchased from Invitrogen. Dulbecco’s minimum 
essential medium (DMEM) with high glucose and DMEM/F12 
were purchased from the Hyclone Corporation. LIF factors, 
SSEA-1, Oct4 and AKP staining reagents were purchased 
from CHEMICON International, Inc.
2.2. Culture of fibrocytes
 
  The liver tissue was cut into pieces, digested and separated 
by 2.5 g/L pancreatin. DMEM with high glucose and DMEM/
F12 were used for cell culture and resuspension. The cells 
were then inoculated into common culture bottles and 
thermostatically cultured at 37 曟. After 1 day, the medium 
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was changed or subcultured according to the density of 
cells[3-5]. The fibrocytes of the 1st and 2nd generation were 
selected and cryopreserved for further use. 
2.3. Induction and packaging of vectors
  Retroviruses plasmid vectors of Sox2, Klf4, Oct4 and 
C-MYC were extracted using plasmid DNA extraction 
kit. The above fibrocytes were virus-packaged by 
LipofectamineTM 2000 and then dyed by green fluorescent 
protein to observe the efficiency of transfection[6].
2.4. Induction of IPS cells
  The fibrocytes of the 1st and 2nd generation were thawed 
and cultured by DMEM with high glucose and DMEM/F12. 
The medium was exchanged once every day. The cells were 
inoculated into six well plates at a density of 3×104 cells/well after 
3 days. Then, the cells were culture for 6 hours in DMEM 
containing 10% FBS. The cells were transfected until the 
confluence area was up to 60%[7]. The transfection continued 
for 18 hours. The cells were transfected again after 6-hour 
culture, followed by further culture. Then the cells were 
passaged and identified after cloning.
2.5. Identification of IPS cells
  The IPS cells were fixed by 4% paraformaldehyde and 
dyed according to the introduction of AKP staining kit after 
20 minutes post fixation[8,9]. After 20-minute incubation, 
the cells were washed by PBS and sealed by glycerin to be 
observed under a microscope. 
2.5.1. RT-PCR
  The RT-PCR primers were designed referring to the 
relevant references. The primer sequences are shown in 
Table 1.
Table 1
Sequences of RT-PCR primers.
Primer Sequence (5′-3′)
hOct4-R GGA GAC AGG GGG AGG GGA GGA GCT AG
hOct4-F GTT CCC TCC AAC CAG TTG CCC CAA AG
hSox2-R GGG AAA TGG GAG GGG TGC AAA AGA GG
hSox2-F TTG GGT GAG TGT GGA TGG GAT TGG TG
hKlf4-R ACG ATC GTG GCC CCG GAA AAG GAC C
hKlf4-F TGA TTG TAG TGC TTT CTG GGG CTC C
2.5.2. Identification of stem cell marker proteins
  SSEA-4, TRA-1-60, TRA-1-81, and specific proteins 
(OCT4 and Nanog) related to stem cell expression were 
detected by immunohistochemistry. Nanog protein was 
detected by Western blotting. Methylation level of Nanog 
gene promoter region was detected by bisulfite-genome 
sequencing method. All kits were purchased from Shanghai 
Stan (stem) Biological Technology Co., Ltd.
2.5.3. Teratoma assay
  First, 1×106-5×106 IPS cells were subcutaneously injected 
into SCID Beige mouse. The formation of subcutaneous 
teratoma was observed after 1 month. The tumor tissue was 
sliced and observed to analyze each germ layer.
2.5.4. Methylation assay
  G9a protein methylation transferase inhibitor was used to 
treat receptor cells to induce reprogramming. 
2.5.5. In vivo identification assay
  The successfully established IPS cells were inoculated into 
the back of nude mice to observe the formation of teratoma 
and subcutaneous tumor[10,11].
3. Results
3.1. Infection of fibrocytes and establishment of IPS cells
  The fibrocytes were infected effectively, and the expression 
of green fluorescence was high, showing high infection 
ability. The IPS cells were successfully established after 
fibrocytes were infected, and round IPS cell clones were 
observed under the microscopy (Figure 1). The induction rate 
was 0.013%±0.007%.
A                                                              B
Figure 1. Microscopic observation of normal fibrocytes (A) and 
pluripotent stem cells induced from fibrocytes (B) (×400).
3.2. Detection of stem cell marker proteins and chromosome 
in established IPS cells 
  Obvious expression of SSEA-4, TRA-1-60, TRA-1-81 and 
Nanog proteins was observed (Figure 2). The IPS cells had 
normal 46xy chromosome, which was the same as that in the 
fibrocytes.
3.3. Teratoma formation in nude mice
  No tumor formation was found at the back of nude mice 
within 8 weeks after the inoculation of cell clones. However, 
teratoma formed in all nude mice within 1 week post the 
inoculation of IPS cells. The diameter of tumor was around 2 
cm after 8 weeks. The nude mouse was killed and the tumor 
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was obtained for observation. After subcutaneous inoculation 
of IPS cells into the nude mouse, HE staining was used to 
observe the teratoma. Three germ layers were found. There 
were gland cells in endoderm, cartilage tissue in mesoderm, 
and hair follicle structure in ectoderm (Figure 3).
AKP                             DAPI                         Merge
Nanog
SSEA-3
SSEA-4
TRA-1-60
TRA-1-81
Figure 2. Expression of stem cell marker proteins in the induced 
pluripotent stem cells.
3
A. Endoderm            B. Mesoderm                 C. Ectoderm
Figure 3. HE staining of teratoma in nude mouse after inoculation of 
induced pluripotent stem cells.
3.4. Subcutaneous tumor formation in nude mice
  No tumor formed subcutaneously in the nude mice within 2 
weeks post the inoculation of fibrocyte cell clones, and only 
one of the five mice had tumors during the last two weeks. In 
contrast, subcutaneous tumors appeared within 1 week after 
the inoculation of IPS cells in all nude mice. The diameter of 
tumor was less than 1 cm, and the tumor was not excised for 
the observation. 
3.5. Methylation of fibrocytes and IPS cells
  Figure 4 shows the methylation of fibrocytes and IPS cells. 
The Nanog and OCT4 showed high methylation status in 
the fibrocytes but low methylation status in the IPS cells, 
indicating that the IPS cells had the same ability as stem 
cells.
Fibrocytes       IPS cells                  Fibrocytes                         IPS cells
(A) Nanog                                                     (B) OCT4
Figure 4. Comparison of methylation of Nanog and OCT4 between 
fibrocytes and induced pluripotent stem (IPS) cells.
4. Discussion
  IPS cells is high self-renewal and has high ability of 
multidirectional differentiation in vitro, which may have 
wide applicable prospects in the treatment of various 
diseases, establishment of disease models and research 
of pathogenic mechanisms[12]. Due to the few obvious 
symptoms of early stage liver cancer, most of patients 
have entered intermediate or advance stage when being 
diagnosed. The liver cancer patients may be too late to 
receive surgical treatment. The patients can only receive 
conservative treatment or wait for liver donors. However, 
compared to the large group of liver cancer patients, the 
amount of liver donors is comparative less, and thus the life 
quality of liver cancer patients cannot be guaranteed[13-15]. 
Subsequently, to establish IPS cells by using fibrocytes has 
become a focal point to promote the regeneration of liver 
and has attracted more attention in clinic.
  IPS cells have been successfully induced in vitro in 
the study of mouse cell sequencing, which made the 
establishment of individual specific IPS cell possible[16-18]. 
The methods using transposable genes and lentiviral vector 
show good effects on the establishment of IPS cells and help 
the obtainment of therapeutic IPS cells[19,20]. We established 
the IPS cells of human liver cancer by using this method, and 
the induction rate was acceptable. The carcinogenicity of 
IPS cells was also decreased to avoid the risk of regenerative 
cells induced tumor emergence[21,22]. Nonetheless, the 
related mechanisms are still uncertain[23]. By observing the 
formation of teratoma and subcutaneous tumor, we found 
the IPS cells had high potency of differentiation in vivo. The 
induced IPS cells had similar pluripotency as embryonic 
stem cells. (i) The fibrocytes had a similar strong infection 
capability as pluripotency stem factors. (ii) The stem cell 
marker proteins including SSEA-4, TRA-1-60, TRA-1-81 
and Nanog were highly expressed in both the IPS cells and 
pluripotency stem cells, as evidenced by RT-PCR. (iii) 
Teratoma appeared in nude mouse within 1 week after the 
inoculation of IPS cells and there were three germ layers 
of tissue cells, showing a strong teratoma formation ability. 
(iv) According to the methylation results, the methylation 
level of Nanog and OCT4 was low in the IPS cells, indicating 
potency of differentiation. Thus, future studies should be 
focused on controlling the differentiation direction of IPS 
cells so as to provide cells of artificial liver. The key points 
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to establish IPS cells are as follows: control on the induction 
level of programming factor; selection of transcription factor 
activity time; selection of the fibrocyte resource; and control 
on induction level[24-26]. In the establishing process of IPS 
cells, the selection of small molecular substances should 
be controlled according to the transcription factor level 
in fibrocytes, in order to increase the induction rate and 
decrease the carcinogenicity of cells[27].
  In conclusion, IPS cells of live cancer patient can be 
effectively established from fibrocytes. The IPS cells can be 
stably subcultured in vitro, which provides possibility for 
the treatment of liver cancer patients in the intermediate 
or advanced stage. In future study, more attention should 
be paid to the control of differentiation direction of IPS 
cells so that safe and clinically applicable IPS cells can be 
developed to improve survival rate.
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